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Abstract
Complex trait genome-wide association studies (GWAS) provide an efficient strategy for evaluating large numbers of
common variants in large numbers of individuals and for identifying trait-associated variants. Nevertheless, GWAS often
leave much of the trait heritability unexplained. We hypothesized that some of this unexplained heritability might be due to
common and rare variants that reside in GWAS identified loci but lack appropriate proxies in modern genotyping arrays. To
assess this hypothesis, we re-examined 7 genes (APOE, APOC1, APOC2, SORT1, LDLR, APOB, and PCSK9) in 5 loci associated
with low-density lipoprotein cholesterol (LDL-C) in multiple GWAS. For each gene, we first catalogued genetic variation by
re-sequencing 256 Sardinian individuals with extreme LDL-C values. Next, we genotyped variants identified by us and by the
1000 Genomes Project (totaling 3,277 SNPs) in 5,524 volunteers. We found that in one locus (PCSK9) the GWAS signal could
be explained by a previously described low-frequency variant and that in three loci (PCSK9, APOE, and LDLR) there were
additional variants independently associated with LDL-C, including a novel and rare LDLR variant that seems specific to
Sardinians. Overall, this more detailed assessment of SNP variation in these loci increased estimates of the heritability of
LDL-C accounted for by these genes from 3.1% to 6.5%. All association signals and the heritability estimates were
successfully confirmed in a sample of ,10,000 Finnish and Norwegian individuals. Our results thus suggest that focusing on
variants accessible via GWAS can lead to clear underestimates of the trait heritability explained by a set of loci. Further, our
results suggest that, as prelude to large-scale sequencing efforts, targeted re-sequencing efforts paired with large-scale
genotyping will increase estimates of complex trait heritability explained by known loci.
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Introduction
In the past few years, genome-wide association studies (GWAS)
have identified hundreds of genetic variants associated with
quantitative traits and diseases, providing valuable information
about their underlying mechanisms (for a recent example, see [1]).
More than 2,000 common variants appear associated with over
200 conditions (as reported by the NHGRI GWAS catalog on 12/
2010) and for a few, like age-related macular degeneration [2] and
type 1 diabetes [3], these common variants already account for a
large fraction of trait heritability. In contrast, for most complex
traits and diseases, common variants identified by GWAS confer
relatively small increments in risk and explain only a small
proportion of trait heritability [4]. For example, for low-density
PLoS Genetics | www.plosgenetics.org 1 July 2011 | Volume 7 | Issue 7 | e1002198lipoprotein cholesterol (LDL-C), GWAS based on up to ,100,000
individuals examined at ,2.5 million common variants [1,5–6],
have identified 35 loci associated with trait variation, with some
also involved in modulating the risk of cardiovascular diseases.
Common variants at these loci are estimated to account for 12.2%
of the variability in LDL-C levels, about one-fourth of its genetic
variance [1]. Several hypotheses have been formulated about the
nature of the remaining heritability of lipid levels and other
complex traits [4,7], ranging from the potential role of copy
number variants to contributions from a large number of common
SNPs each with very small effects. In our view, common and rare
variants that are poorly represented in common genotyping arrays
might account for an important fraction of trait heritability.
Ignoring these variants might not only preclude identification of
important trait associated loci but also compromise estimates of
heritability. Thus, fine mapping appears the logical next step after
GWAS. Here, we have focused on seven genes located in five of
the loci associated with LDL-C in our original GWAS for blood
lipid levels (APOE, APOC1, APOC2, SORT1, LDLR, APOB and
PCSK9) [5]. A sixth locus (corresponding to SNP rs16996148) that
included a large number of genes and no obvious functional
candidates was not further examined here. Together, the 5 SNPs
identified in the original GWAS analyses of these 5 loci in .8,000
individuals (with follow-up genotyping of .10,000 individuals)
explained only 3.1% of LDL-C variability. We set out to re-assess
the contribution of these loci to trait heritability by evaluating a
broader spectrum of variants. To catalog genetic variation in these
regions, we first sequenced the exons and flankingregionsofthe seven
genes in 256 unrelated Sardinians [8], each with extremely low or
high LDL-C, and in an additional 120 HapMap samples (parents
from the 30 CEU and 30 YRI trios). To assess the effect of identified
polymorphisms, we genotyped detected variants and additional
variants selected based on an early release of the 1000 Genomes
Project in a cohort of 5,524 volunteers from the SardiNIA project [8].
Our results show that at these five loci, a combination of rare and
common variants, some novel and some previously identified, are
associated with LDL-C, and that, taken together they double the
variance explained by the common variants detected in GWAS.
Results
To refine the contribution of five loci implicated by GWAS in
the variability of LDL-C, we sequenced the exons and flanking
regions of seven genes in 256 unrelated Sardinians [8] with LDL-
C levels that were either extremely low (116 individuals, mean
LDL-C=70.4616.0 mg/dl) or high (140 individuals, mean LDL-
C=205.9619.6 mg/dl) (Materials and Methods), as well as an
additional 120 HapMap samples (parents from the 30 CEU and
30 YRI trios). Observed heterozygosity per base pair per
individual was 1.28610
23 in the selected Sardinian individuals,
1.31610
23 in the CEU and 1.99610
23 in the YRI.
Sequencing identified 782 variants, all submitted to dbSNP and
now included in dbSNP releases 130 and later (for a complete list
see Table S1). As expected, more variants were found in the
HapMap YRI samples than in the HapMap CEU or in Sardinian
individuals with extreme lipid levels (Table S2). Overall, we
observed a 2:1 trend for enrichment of rare variants (MAF,1%)
in the high LDL-C group compared to the low LDL-C group,
similar to the observation by Johansen and colleagues [9] (Table
S3), but this enrichment was only statistically significant for APOB
(P=0.03 using an exact test). To test for LDL-C association, we
used logistic regression to compare individuals in the two
categories, yielding 10 variants (in APOE, APOC1, SORT1, APOB,
and PCKS9) with P,0.1 (Table S4). Because of the modest number
of sequenced individuals and because no signal reached signifi-
cance after Bonferroni adjustment, we judged these initial
association analyses – which focused only on sequenced samples
and only at coding regions – inconclusive.
In addition to the loci discussed so far, our re-sequencing and
genotyping effort also included B3GALT4 and B4GALT4, two loci
that approached genome-wide significance in our initial GWAS
analysis (each with 5610
28,p,5610
26) [5]. SNPs in these loci
did not reach genome-wide significance in two subsequent meta-
analyses [1,6] and were not significantly associated with LDL-C in
the data generated here (Table 1 and Figure S1). Because we have
no evidence that these two genes are associated with LDL-C, they
are not discussed further. Variants identified in the two genes were
also deposited in dbSNP.
To increase the power to detect association, we genotyped 5,524
individuals in the SardiNIA cohort [8] using the Metabochip (see
Materials and Methods). The chip included 285 variants newly
discovered by sequencing, together with an additional 2,992
derived from an early analysis of 1000 Genome Project Pilot
haplotypes (considering variants 6250 Kb from each gene). Of
the 3,277 SNPs that were genotyped, 1,868 passed quality control
filters (see Materials and Methods and Table S5). To further
supplement the number of variants at each locus, we carried out
two rounds of genotype imputation. First, we used haplotypes for
256 sequenced SardiNIA samples to impute genotypes for SNPs
that failed assay design or genotyping on the Metabochip. Second,
using the haplotypes of 60 CEU samples from the 1000 Genomes
Pilot, we successfully imputed an additional 5,066 variants [10]
(Materials and Methods and Table S5). After imputation, 7,488
SNPs were available for analysis, with an average minor allele
frequency of 18% and an average imputation r
2 of 0.84 for 5,620
imputed SNPs (554 and 5,066 from Sanger and 1000 Genomes
imputations, respectively; see Table S5 for gene specific counts).
At three loci, SORT1, APOB and LDLR, GWAS-identified
variants were very strong proxies for the best available association
signal, with similar allele frequencies and r
2.0.88 (Table 1,
Figure 1A and Figure S2). In those three genes, the variant
showing strongest association was non-coding and not in strong
linkage disequilibrium (r
2.0.4) with any tested coding variant.
Author Summary
Despite the striking success of genome-wide association
studies in identifying genetic loci associated with common
complex traits and diseases, much of the heritable risk for
these traits and diseases remains unexplained. A higher
resolution investigation of the genome through sequenc-
ing studies is expected to clarify the sources of this missing
heritability. As a preview of what we might learn in these
more detailed assessments of genetic variation, we used
sequencing to identify potentially interesting variants in
seven genes associated with low-density lipoprotein
cholesterol (LDL-C) in 256 Sardinian individuals with
extreme LDL-C levels, followed by large scale genotyping
in 5,524 individuals, to examine newly discovered and
previously described variants. We found that a combina-
tion of common and rare variants in these loci contributes
to variation in LDL-C levels, and also that the initial
estimate of the heritability explained by these loci
doubled. Importantly, our results include a Sardinian-
specific rare variant, highlighting the need for sequencing
studies in isolated populations. Our results provide insights
about what extensive whole-genome sequencing efforts
are likely to reveal for the understanding of the genetic
architecture of complex traits.
Reassessing Heritability at LDL-C Associated Loci
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PLoS Genetics | www.plosgenetics.org 4 July 2011 | Volume 7 | Issue 7 | e1002198The most strongly associated marker at the SORT1 locus,
rs583104 (p-value=1.2610
29) was in high LD (r
2=0.77) with
rs12740374 (p-value=2.2610
28), an intronic SNP in the CELSR2
gene that alters the hepatic expression of the SORT1 gene by
creating a C/EBP (CCAAT/enhancer binding protein) transcrip-
tion factor binding site [11]. Both markers were genotyped, so that
under the hypothesis that rs12740374 is the causal variant
underlying this association signal, the modest difference in p-
values may be attributable to statistical fluctuation.
At the remaining two loci, APOE and PCSK9, evidence for
association peaked at low frequency (1–5%) variants not in strong
linkage disequilibrium with the original GWAS signals. In both
cases our analyses pointed to variants that were well studied in
other contexts, but which are not included in typical GWAS
panels or in the HapMap panel of European haplotypes
commonly used to impute missing genotypes. Thus these variants
were missed in previous GWAS analyses. In PCSK9, variant
rs11591147, which leads to a non-synonymous R46L change in
exon 1, was more strongly associated (P=2.9610
215, frequency
(T)=0.037, effect=212.9 mg/dl; Table 1) than GWAS variant
rs11206510, a SNP ,10 Kb upstream of the transcription start
site of the gene (P=5.7610
27, frequency (C)=0.24, effect
=23.7 mg/dl) (Figure 1C). Furthermore, rs11591147 explained
the GWAS association signal (association at GWAS variant
rs11206510 became non-significant (P=0.013) when non-synon-
ymous variant R46L/rs11591147 was included as a covariate,
Figure 1D). This coding variant has been previously implicated in
the regulation of blood lipid levels, including LDL-C, and in the
susceptibility to coronary and ischemic heart disease [12–13]. At
the APOE gene cluster, the strongest evidence of association was
observed at the missense variant (R176C, also known as R158C [14])
rs7412 (P=1.8 610
231, frequency (T)=0.037, effect=218.8 mg/dl)
(Figure 1E). This variant did not account for the previously reported
GWAS signal; marker rs4420638 indeed remained significantly
associated (P=6.4 610
210) after adjusting for rs7412. The missense
variants at APOE and PCSK9 were not typed in the HapMap II data
set, and were only recently added to genotyping arrays (Illumina
1MDuo). Thus they have not been assessed by any GWAS reported
to date.
We next conditioned on the top association signal at each of the
5 loci and sought to identify additional independently associated
variants. To declare statistical significance at secondary signals, we
used a p-value threshold of 1610
24; corresponding to an
adjustment for 500 independent tests across the five regions
examined. At LDLR, we found an independently associated rare
missense variant (rs72658864/V578A, P=2.5610
26 in the basic
model, P=3.9610
26 in the conditional model, frequency
(C)=0.005; effect=23.7 mg/dl) (Table 1 and Figure 1B). This
variant appears to be specific to Sardinia (where we identified it in
our SardiNIA cohort [8] by Sanger sequencing in 3 out of 256
individuals with extreme LDL-C; by Illumina genotyping in 51 out
of 5,800 randomly ascertained individuals; and by Solexa
sequencing in 1 out of 505 individuals, unpublished data). It is
absent in the HapMap data set, not detected in 280 Northern
European individuals sequenced within the 1000 Genomes
Project, and monomorphic in .10,000 Finnish [15–16] and
Norwegian [17–19] individuals genotyped with the MetaboChip
(Materials and Methods, Table S6 and Table S7). Reassuringly,
the variant was also observed, albeit with a lower frequency
(0.00035), in TaqMan genotyping an independent sample of 5,661
Sardinians from different villages in Sardinia [20] (Materials and
Methods). The change in lipid levels associated with this rare
variant (23.7 mg/dl) is 4 times greater than that observed for the
strongest associated common variant at the locus (5.7 mg/dl for
rs73015013). At the APOE locus, we found a strong independent
signal at non-synonymous variant rs429358 (C130R, also known
as C112R [14]) (Table 1 and Figure 1F)(P=1.2610
212 in the
basic model, P=5.8610
211 in the conditional analysis, frequency
(C)=0.071, effect=9.3 mg/dl), which, together with rs7412,
defines the three major isoforms of APOE (e2, e3 and e4)
[14,21]. This variant strongly correlates (r
2=0.96) with the
originally reported GWAS signal, rs4420638 (P=4.6610
212,
frequency (G)=0.097, effect=7.8 mg/dl). So, at this locus, the
initial GWAS analysis picked up one independent signal (a proxy
of rs429358/C130R) but missed the strongest associated variant in
the region (rs7412/R176C). There was no clear evidence for
residual association after accounting for the two missense variants
(Figure S3). Interestingly, the frequency of the derived allele C at
rs429358 was remarkably lower in Sardinia (freq=0.07, see
Table 1) than that observed in the Finnish and Norwegian
individuals (see Table S7) and several other European ancestry
samples (freq,0.20) [22–24], resulting in a strikingly lower
frequency of the e4 haplotype (2.5% vs. 15%) [22]. Finally, at
PCSK9, we observed a possible independent association at SNP
rs2479415, in the non-coding region flanking the transcript
(P=1.1610
27 in the basic model, P=8 610
25 in the conditional
model, frequency (T)=0.59, effect=23.6 mg/dl) (Table 1 and
Figure 1D). This variant showed an independent trend also in
,10,000 Finnish and Norwegian individuals (one-sided P=0.055
after conditioning for rs11591147).
When the 5 GWAS SNPs were replaced by the 8 variants
described here (1 each for SORT1 and APOB, 2 for APOE, PCSK9
and LDLR) the variance accounted for by those loci increased from
3.1% to 6.5%. Similar estimates were also obtained with ,10,000
Finnish and Norwegian individuals, where, on average, analysis of
these 8 variants increased variance explained from 3.5% to 7.1%
(Table 2 and Materials and Methods).
Discussion
We conducted fine mapping of five loci associated with LDL-C
at an unprecedented level of resolution. In particular, we
sequenced individuals with extreme phenotype levels, and
subsequently genotyped variants identified by us and by the
1000 Genomes Project in a larger sample. In a final step we also
imputed additional variants in the region to account for limitations
of genotyping assay design. At all but one of the loci, APOB, the
most strongly associated variant was directly genotyped or
sequenced, suggesting that our initial selection included the crucial
variants. In three loci, we found strongly associated rare or low
frequency variants – which (except for a variant in LDLR, which
appears to be specific to Sardinia) had been extensively
Figure 1. Regional Association plots. Association results around LDLR, PCSK9 cluster and APOE. In each panel, the box at left (A, C and E) shows
the association results in the main analysis; and at right (B, D and F) the results after conditioning for the strongest associated variant, highlighted
with a purple dot in both plots, and its name written at the top. Arrows highlight independent signals and the most associated SNP detected in the
previous GWAS [5]. Each SNP is also colored according to its LD (r
2) in Sardinians with the top variant, with symbols that reflect genomic annotation
as indicated in the legend. The rugs above indicate the position of the SNPs that were analyzed by direct typing (MetaboChip), or imputed by using
haplotypes from sequenced samples (Affy+Sanger) or 1000 Genomes haplotypes (1000G). Plots were drawn using the LocusZoom standalone version
[37]. Genomic coordinates are given according to build 36 (hg18).
doi:10.1371/journal.pgen.1002198.g001
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although the associated variants had been previously described,
they had not been thoroughly examined in together with GWAS
associated variants at the same loci – so that the relative
contributions of GWAS identified SNPs and previously described
variants remained unclear.
In summary, we observed that:
(a) At SORT1 and APOB loci, association peaked at variants
with similar effect size and frequency to the variants
identified in GWAS;
(b) At the LDLR locus, in addition to confirming the GWAS
signal, a rare variant with a large effect was found. This
variant is currently unique to the island of Sardinia;
(c) At the APOE locus, an independently associated low
frequency variant was identified. The signal was previously
missed in GWAS because the variant was not included in the
available genotyping chips or in the HapMap reference
panels. An independently associated common variant similar
in frequency and effect size to the original GWAS signal was
also identified.
(d) At the last locus, PCSK9, the GWAS signal could be
explained by a low frequency coding variant not included in
the available GWAS genotyping chips or in the HapMap
reference panels. Furthermore, there was evidence for one
other independently associated variant.
The strongest signals identified at APOE (both variants) and
PCSK9 (the top hit) are likely to be the causal variants underlying
the association signals. For SORT1, the variant exhibiting strongest
association appears to be in strong linkage disequilibrium with a
recently proposed functional polymorphism. In contrast, biological
interpretation remains unclear for the other identified polymor-
phisms and requires further studies. Our results lead to several
important major conclusions. First, it is striking that prior LDL-C
GWAS have often missed signals due to low frequency variants (in
two of the loci examined here, we identified strongly associated
variants with frequency 1–5% that were missed in the original
GWAS, because they were untyped or missing on imputation
panels and poorly tagged by nearby SNPs). Sequencing in
individuals with extreme trait values, along with large-scale
imputation and genotyping, provided a better evaluation of the
contribution of these loci to variation in LDL-C levels. A similar
design was recently used to fine-map loci associated with fetal
hemoglobin levels, a trait for which three loci can now account for
about half of total variance [25].
Second, we show that in one of the five loci we fine-mapped, a
previously missed low frequency variant can account for the
GWAS signal – consistent with the hypothesis that at least some
GWAS signals will be due to disequilibrium with nearby low
frequency or rare variants [26]. There is considerable debate on
how frequently this scenario will occur [27]. Our observations are
compatible with some of the arguments made on both sides of this
debate [26–27]. For example, in the case of PCSK9, a single low
frequency variant explains the observed common variant associ-
ation signal but did not appear to reduce the ability of the genome-
wide association study to localize the functional element of
interest. Furthermore, the effect of this variant was too small to be
detectable in most linkage studies (including our own linkage
analysis of .35,000 relative pairs in Sardinia). Further, a single
low frequency variant (and not a cluster of variants) was sufficient
to explain this association signal.
Finally, our results show that if estimates are based only on the
common variation assessed through GWAS, heritability at
identified loci is likely to be underestimated. A more complete
dissection, including common, low frequency and rare variants
(some of which will be population specific), dramatically increased
the proportion of heritability associated with the 5 loci examined
here, from 3.1% to 6.5%. Notably, the variance explained by each
locus increased when a rare variant was found as a primary or
secondary hit (LDLR, APOE and PCSK9), even when the top
GWAS SNP highly correlates with a strong association signal
(LDLR and APOE). By contrast, only slight improvements were
observed at loci where the most associated marker highly
correlated with the GWAS SNPs and there was no evidence for
additional independent signals, even when the GWAS variant is
unlikely to be functional (SORT1 and APOB).
Genome-wide association studies have proven to be an
extremely productive strategy for identifying regions of the
genome associated with complex traits, often leading to unexpect-
ed insights into complex trait biology. A major efficiency of these
studies is that, by focusing on a subset of variants that can be
genotyped using array based platforms, they can conveniently and
economically survey many common variants in large numbers of
individuals. Our results emphasize the utility of these genome-wide
studies in identifying trait association regions, but also emphasize
that caution is needed when genome-wide study results are used to
quantify the overall contribution of a locus to trait heritability. In
our opinion, and consistent with our results, accurate estimates of
heritability will require more extensive examination of each
identified locus.
Broadly, this observation is consistent with recent simulation
studies [28] which explore, in the context of a dichotomous trait,
the relationship between effect sizes observed at GWAS SNPs and
at true causal variants for the same locus. These simulation studies
suggest that, most of the time, effect sizes estimated from GWAS
Table 2. Heritability estimates in all study samples.
Study N samples Variance explained by 5 GWAS SNPs Variance explained by 8 SNPs
SardiNIA 5,382 3.1% 6.5%
Norwegian T2D 1,171 5.8% 9.3%
Norwegian controls 1,436 3.1% 8.5%
Finnish T2D 1,742 2.1% 5.0%
Finnish controls 5,678 3.4% 7.0%
Average Finnish and Norwegian 10,027 3.5% 7.1%
The table shows the LDL-C variance accounted for by the 5 GWAS SNPs and the 8 SNPs here described in all studies. A sample size weighted average estimate is given
for the Finnish and Norwegian samples.
doi:10.1371/journal.pgen.1002198.t002
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effect sizes estimated from GWAS might substantially underesti-
mate the true effect size – especially in a scenario where rare
variants are more likely to be causal. In cases where the effect size
was underestimated by GWAS variants, a noticeable increase in
heritability ensues.
It is also interesting to note that the effect sizes estimated here
for rare and low frequency variants (all .10 mg/dl) are larger
than the effect sizes of any of the common variants identified in
GWAS studies. Effect sizes of more rare alleles associated with
familial hypercholesterolemia are even larger (see [29] for
examples of PCSK9 variants with effects .100 mg/dl). This is
consistent with the intuition that alleles with a large impact on
LDL-C levels will be under strong natural selection and will, thus,
be prevented from reaching high frequency in the population.
Although rare and low frequency alleles with more modest impacts
on LDL-C values are also likely to exist, we cannot detect them
using available sample sizes and their detection must await studies
of much larger sample sizes.
In conclusion, these results underline that the subsequent
sequencing of the coding regions around GWAS associations in
individuals with extreme values followed by large scale imputation
and genotyping is an important step in assessing the contribution
of associated genomic regions to trait heritability. If similar trends
to those described here are observed at the remaining LDL-C
associated loci, extending our approach described to all known
LDL-C susceptibility loci could lead to an increase in the
proportion of variance they explain from ,12% to ,24%,
exceeding half of the genetic variance for this trait. Due to
economic considerations, our sequencing efforts focused on the
coding regions of each gene and only on genes that appeared very
likely to be involved in lipid metabolism. In each locus, we
augmented the set of discovered variants with variants discovered
by the 1000 Genomes Project, but that will likely miss very rare as
well as population specific variants. We expect that more extensive
fine-mapping efforts that more comprehensively examine non-
coding regions could identify additional trait associated variants.
Ultimately, unbiased whole genome sequencing based association
analyses might be required to fully explain the heritability of a trait
like LDL-C, facilitating the comprehensive assessment of rare,
population specific, and non-SNP variation. In the meantime,
directed sequencing and large scale genotyping appears to be a
promising approach.
Materials and Methods
Ethics statement
All individuals studied and all analyses on their samples were
done according to the Declaration of Helsinki and were approved
by the local medical ethics and institutional review committees.
Samples description
The SardiNIA project is a population based study of aging-
related traits that includes 6,148 related individuals from the
Ogliastra region of Sardinia, Italy [8,30]. During physical
examination, a blood sample was collected from each individual
and divided into two aliquots, one for DNA extraction and the
other to characterize several blood phenotypes, including lipids
levels. Specifically, LDL-C values were derived using the
Friedwald formula that combines HDL and total cholesterol
levels. The Finnish and Norwegian individuals are Type 2
Diabetes patients and unaffected individuals collected from several
studies. Specifically, Finnish studies are: Dehko 2D 2007 (D2D
2007), Dose Responses to Exercise Training (DrsEXTRA),
Diabetes Prevention Study (DPS), FUSION stage 2 [15] samples
(from ACTION LADA, D2D 2004, FINRISK 1987, FINRISK
2002, Health 2000, Savitaipale) and Metabolic Syndrome in Men
(METSIM) [16]; Norwegian studies are: The Nord- Trøndelag
Health Study (HUNT 2) [17–18] and The Tromsø Study
(TROMSØ) [19]. Baseline clinic characteristics of the SardiNIA,
Finnish and Norwegian studies are reported in Table S7.
The independent Sardinian sample used for assessing the
frequency of the rare variant at LDLR consists of 5,661 individuals
belonging to 884 families enrolled in the SharDNA study [20],
which recruited volunteers from a cluster of villages located in the
Ogliastra region: Talana, Urzulei, Baunei, Triei, Seui, Seulo,
Ussassai, Perdasdefogu, Escalaplano and Loceri. Observed
heterozygotes were unrelated to those observed in the SardiNIA
study based on demographic records to track origin of individuals
up to 10 generations.
Sequencing
Sequencing of the 256 Sardinians and the 120 HapMap
samples (parents from the 30 CEU and 30 YRI trios) was carried
out at the University of Washington Genome Sequencing Center
through the NHLBI Resequencing & Genotyping Service (Debbie
Nickerson, PI). To select the 256 individuals to be sequenced, we
adjusted LDL levels by age and sex and then identified individuals
in the top and bottom 5% of the distribution (individuals under
lipid-lowering therapy were not considered). Among those, we
selected all unrelated individuals who had at least one sibling in the
study and were genotyped with 500 K or 10 K arrays [30], to
facilitate downstream follow-up and imputation analyses.
Among the 782 variants detected by sequencing, two loss-of-
function variants were observed. However, these were identified
only on HapMap samples (see Table S8). A common in-frame
insertion in APOB was observed in Sardinia and in HapMap CEU
samples but was not associated with LDL-C after multiple testing
adjustment (rs17240441, P=3.0610
24; see Figure S1C and S1D,
Table S8). The observed heterozygosity per bp/per individual was
0.00128, 0.00131 and 0.00199 in Sardinia, CEU and YRI
samples, respectively. Concordance rate of HapMap II and III
phases genotypes with those obtained from Sanger sequencing was
99.63%, while a lower rate (98.1%) was observed with genotypes
obtained from the low-pass sequencing 1000 Genomes Project (43
CEU and 42 YRI samples were common between the two
datasets), indicating the slightly lower accuracy of next-generation
sequencing technologies and in particular of low-pass sequencing
approaches [31].
Genotyping
Genotyping was carried out with Metabochip arrays (Illumina),
which were designed in collaboration with several international
consortia [5,32–33] with the aim to fine map association loci
detected through GWAS for a variety of traits. Part of the design
included a set of wild-card SNPs chosen by individual research
groups, and the SardiNIA study promoted the inclusion of all
variants detected by sequencing individuals with extreme LDL-C
values. In particular, assays were successfully designed for 285 of
the 782 variants discovered by sequencing and 178 passed quality
controls filters (some of those were polymorphic only in HapMap
individuals, but we included all detected variants on the chip to
assess heterozygosity on a large sample). Briefly, 3,277 variants
were included on MetaboChip, and 1,868 passed quality checks.
For a detailed description of markers discarded by each filter see
Table S9. Concordance rate of Sanger and Metabochip genotypes
was 99.47% at QCed markers, evaluated comparing genotypes of
the 256 sequenced samples.
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HD Assay protocol with Multisample Beadchip format, and
GenomeStudio was used for genotype calling. All samples had a
call rate.98%, and there was no evidence for mis-specified family
relationships (evaluated using Relpair software [34]). We discarded
markers if any of the following was true: a) call rate ,95%, b)
MAF=0, c) Hardy-Weinberg Equilibrium P,10
26 or d) excess of
Mendelian Errors (Table S9).
A total of 5,524 Sardinian individuals were genotyped, of which
5,382 had lipid measurements available and were not under lipid
lowering therapy. In the Finnish and Norwegian studies, a total of
10,823 samples were genotyped, of which 10,027 had LDL-C
measurement available and were not under lipid lowering therapy.
Genotyping of the rare LDLR variant rs72658864 on the
SharDNA samples was carried out using TaqMan single SNP
genotyping assays (Applied Biosystems). Given the rarity of the
variant, DNA of a known heterozygote from the SardiNIA project
was included in each well plate to allow detection of intensities of
both alleles. The genotype of this sample was called as
heterozygote in all plates.
Imputation and statistical analyses
To better represent genomic variation, we merged genotypes
from the 256 sequenced Sardinian samples with genotypes
available from Affymetrix 500 K [30] and/or Metabochip for all
variants +/22 Mb spanning the gene’s transcript. We then phased
the haplotypes using MACH [10] and used this reference set of
haplotypes to impute sequence variants in the rest of the cohort
[35]. We then focused on variants within +/250 Kb of the gene
transcript. To further fine map the region, we used 120 haplotypes
from the 60 CEU samples sequenced within the 1000 Genomes
Project (June 2010 release of haplotypes based on March 2010
genotypes release) to impute variants outside the coding regions
and flanking sequences targeted in our sequencing study. MACH
software was used for imputation, with the same sized window
used for the Sardinian-based imputation (+/22 Mb). The results
obtained with these two rounds of imputation are identified in the
text, as well in table and figure legends, as ‘‘Affy+Sanger’’ and
‘‘1000G’’, respectively.
For association, LDL-C levels were adjusted for age, age
squared and sex, and the distribution of residuals was normalized
using a quantile transformation. The association test was
performed using Merlin (–fastassoc option), which uses a variance
component framework to account for genetic correlation across
family members [35–36].
Comparison of imputed genotypes with experimental geno-
types, carried out on a set of 1,097 individuals that were genotyped
with the 6.0 Affymetrix Arrays (unpublished data), showed that the
average per genotype error rate between imputed and exper-
imental genotypes was 3.7% and 4.1% for imputations based on
1000 Genomes and Sanger haplotypes, respectively.
In the Finnish and Norwegian studies we applied a similar
strategy to analyze variants (rs547235 and rs562338 on APOB,
rs2479415 on PCSK9 and rs429358 on APOE) that were not
included on Metabochip. We defined a set of reference haplotypes
of the 60 HapMap CEU founders by merging genotypes from the
1000 Genomes project and those from our Sanger sequencing,
using SNPs located +/22M bo fAPOB, PCSK9 and APOE.W e
then used this reference panel to carry out imputation and
successively used imputed dosages for testing association with
LDL-C. Association analysis was performed using the same trait
transformation and covariates as in the SardiNIA study.
Imputation and association tests were performed separately for
Finnish diabetics (N=1,742), Finnish non-diabetics (N=5,678),
Norwegian diabetics (N=1,171) and Norwegian non-diabetics
(N=1,436). Results were then meta-analyzed using an inverse-
variance method, which combines p-values from each study using
weights proportional to the variance of the beta coefficient (effect)
(Table S7). A combined estimate of allele frequencies was obtained
using the same weights.
Variance explained
We evaluated the variance explained by a set of markers by
including all of them into the linear model in addition to the
clinical covariates (age, age squared, gender), and by subtracting
the variance explained by this model versus the basic model (only
clinical covariates). Analyses were performed using the lmekin
function in R kinship package which uses a variance component
framework to account for genetic correlation across family
members. In particular, since variance is not purely additive
across loci, heritability in Table 2 has been calculated using all 8
SNPs (or 5 SNPs) in the model rather than adding values observed
at specific loci (Table 1). For the Finnish and Norwegian samples,
the LDL-C variance explained was calculated in each study group
separately, and a combined estimate was calculated by weighting
each study according to its sample size (Table 2).
Conditional analyses
We conducted conditional analyses to test for residual
associations after accounting for a key SNP. The procedure
consists of adding a SNP into the regression model as covariate
and testing the effect of another SNP. Specifically, we performed
this analysis by adding the strongest associated variant (key SNP)
as covariate in order to test 1) whether that variant could explain
the GWAS association signal; and 2) if additional independent
signals were present. For the latter analysis, a threshold of
P,1610
24 was used to declare significance, corresponding to a
Bonferroni threshold for 500 independent tests. A graphical
representation of association results from the conditional analysis is
shown in Figure 1B, 1D, 1F and in Figure S2B and Figure S2D.
URLs
MACH software: http://www.sph.umich.edu/csg/abecasis/
mach/;
HapMap project: http://www.hapmap.org/;
1000 Genomes Project: http://www.1000genomes.org/;
1000 Genomes Haplotypes for imputation:
http://www.sph.umich.edu/csg/abecasis/MACH/download/
1000G-2010-06.html;
Locus Zoom: http://csg.sph.umich.edu/locuszoom/
R kinship package http://cran.r-project.org/web/packages/
kinship/index.html
Supporting Information
Figure S1 Association results at B4GALT4(A) and B3GALT4 (B).
Similarly to Figure 1, the strongest associated variant is highlighted
with a purple dot, and its name written nearby. Arrows highlight
independent signals and the most associated SNP detected in our
original GWAS. Each SNP is also colored according with its LD
(r
2) in Sardinians with the top variants, with symbols that reflect
genomic annotation, as in Figure 1. The rugs on top indicate the
position of the SNPs that were analyzed by direct typing
(MetaboChip), imputed by using haplotypes from sequenced
samples (Affy+Sanger) or imputed by using 1000 Genomes
haplotypes (1000G).
(TIF)
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Figure 1, the box at left (A and C) shows the association results in the
main analysis; and at right (B and D) show the results after
conditioning for the strongest associated variant, highlighted with a
purple dot in both plots, and its name written at the top. Arrows
highlight the independent signal (if any) and the most associated SNP
detected in our original GWAS. Each SNP is also colored according
with its LD (r
2) in Sardinians with the top variant (used as covariate),
with symbols that reflect genomic annotation, as indicated in the
legend in panel A. The rugs on top indicate the position of the SNPs
that were analyzed by direct typing (MetaboChip), imputed by using
haplotypes from sequenced samples (Affy+Sanger) or imputed by
using 1000 Genomes haplotypes (1000G).
(TIF)
Figure S3 Association results at APOE after adjusting for the two
missense variants. The figure shows the association results at APOE
after adjusting for the two independent signals rs7412 (indicated with a
purple dot) and rs429358 indicated with an arrow. Each SNP is also
colored according with its LD (r
2) in Sardinians with the top variant
(rs7412) in the main analysis, with symbols that reflect genomic
annotation, as indicated in the legend. The rugs on top indicate the
position of the SNPs that were analyzed bydirect typing (MetaboChip),
imputed by using haplotypes from sequenced samples (Affy+Sanger) or
imputed by using 1000 Genomes haplotypes (1000G).
(TIF)
Table S1 List of all variants detected by sequencing in the 256
Sardinians and 120 HapMap Samples and relative counts (given
on a separate excel file). The table lists the variants detected by
Sanger sequencing, their genomic position in build 36, the
corresponding alleles, the biological function and the observed
frequency in Sardinians, CEU and YRI samples.
(XLS)
Table S2 Summary of variants detected by sequencing in the 256
Sardinians and 120 HapMap Samples. The table summarizes the
variants detected by sequencing in different types of biological function.
(DOCX)
Table S3 Enrichment of rare variants (MAF,0.01). The table
lists the number of carriers of coding mutations (MAF,0.01) for
each gene in individuals with high or low LDL-C levels. Shaded
rows indicate whether a trend for enrichment is observed,
although significance was clear only at APOB.
(DOCX)
Table S4 Case-control association analysis results. Association
signals showing a p-value,0.1 when comparing individuals with
high and low LDL values.
(DOCX)
Table S5 Statistics of detected genotyped and imputed SNPs for
each region (+/2250 Kb from gene’s transcript). The table
summarizes the variants detected and analyzed in each step
(sequencing, genotyping, imputation) for each gene.
(DOCX)
Table S6 Clinical characteristics of study cohorts. The table
describes the clinical characteristics for the Sardinians, Finnish and
Norwegian populations used for association analyses.
(DOCX)
Table S7 Association results in the Finnish and Norwegian
individuals. The table describes the association results for all SNPs
in the diabetics and non-diabetics Finnish and Norwegian samples.
(DOCX)
Table S8 Loss-of-function and in-frame insertion variants
identified by sequencing and their respective frequencies on each
population. The table reports the specific loss-of-function and in-
frame insertion variants detected in APOB and PCSK9 genes, their
genomic position in build36 and frequencies in the 256 Sardinians
and 120 CEU and YRI populations.
(DOCX)
Table S9 Metabochip Genotype Quality Control Details.
Statistics of quality controls filters. Note that a marker could have
failed more than one check.
(DOCX)
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